Atypical linear toxicodermia by sorafenib.
Rodríguez-Vázquez
María
M
Martinez-Martínez
María Luisa
ML
García-Arpa
Mónica
M
De Onzoño
Luis Iñiguez
LI
D000328:Adult; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D004487:Edema / Q000139:chemically induced; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D017444:Skin Diseases, Papulosquamous / Q000139:chemically induced*; D000077157:Sorafenib
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib